Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$13.52 USD
-0.23 (-1.64%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $14.82 +1.31 (9.66%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Edgewise Therapeutics, Inc. has a market cap of $1.45B, which represents its share price of $13.74 multiplied by its outstanding shares number of 105.20M. As a small-cap company, EWTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
EWTX 13.52 -0.23(-1.64%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Other News for EWTX
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
Raymond James Initiates Coverage on Edgewise Therapeutics (EWTX) with Strong Buy
Edgewise Therapeutics initiated with bullish view at Raymond James, here's why
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc